CoChat

Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype

Open access
Parween, Shaheena, Fernández-Cancio, Mónica, Benito-Sanz, Sara, Camats, Núria, Rojas Velazquez, Maria Natalia, López-Siguero, Juan-Pedro, Udhane, Sameer S, Kagawa, Norio, Flück, Christa E, Audí, Laura, Pandey, Amit V · 2020 · The Journal of Clinical Endocrinology & Metabolism

Published version of a preprint

Cited by 28

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Context: Mutations in cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We report a novel R550W mutation in POR identified in a 46,XX patient with signs of aromatase deficiency. Objective: Analysis of aromatase deficiency from the R550W mutation in POR. Design, setting, and patient: Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C > T/p.R550W in POR. Wild-type and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children’s Hospital, Bern, Switzerland. Main outcome measure and Results: POR-R550W showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity, and CYP17A1 as well as CYP21A2 activities were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed. Conclusions: Pathological effects due to POR-R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaa076

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 42

  1. Pandey, 2004, P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes, Endocr Res., 30, 881, 10.1081/ERC-200044134 · DOI · Paper page
  2. Fukami, 2014, Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects, Pediatr Int., 56, 805, 10.1111/ped.12518 · DOI · Paper page
  3. Fukami, 2009, Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients, J Clin Endocrinol Metab., 94, 1723, 10.1210/jc.2008-2816 · DOI · Paper page
  4. Lu, 1969, Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components, J Biol Chem., 244, 3714, 10.1016/S0021-9258(18)83427-5 · DOI · Paper page
  5. Murataliev, 2000, Interaction of NADP(H) with oxidized and reduced P450 reductase during catalysis. Studies with nucleotide analogues, Biochemistry., 39, 5066, 10.1021/bi992917k · DOI
  6. Masters, 2005, The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases, Biochem Biophys Res Commun., 338, 507, 10.1016/j.bbrc.2005.09.165 · DOI
  7. Flück, 2011, Clinical and biochemical consequences of p450 oxidoreductase deficiency, Endocr Dev., 20, 63, 10.1159/000321221 · DOI · Paper page
  8. Flück, 2008, P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia, Endocr Dev., 13, 67, 10.1159/000134826 · DOI · Paper page
  9. Flück, 2007, Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase, Fundam Clin Pharmacol., 21, 399, 10.1111/j.1472-8206.2007.00520.x · DOI · Paper page
  10. Agrawal, 2010, Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase, Pharmacogenet Genomics., 20, 611, 10.1097/FPC.0b013e32833e0cb5 · DOI · Paper page
  11. Flück, 2017, Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase, J Steroid Biochem Mol Biol., 165, 64, 10.1016/j.jsbmb.2016.03.031 · DOI
  12. Flück, 2011, Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency, Biochem Biophys Res Commun., 412, 572, 10.1016/j.bbrc.2011.08.001 · DOI
  13. Simpson, 1994, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr Rev., 15, 342
  14. Bilezikian, 1998, Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency, N Engl J Med., 339, 599, 10.1056/NEJM199808273390905 · DOI · Paper page
  15. Rochira, 2002, Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones, J Clin Endocrinol Metab., 87, 2857, 10.1210/jcem.87.6.8556 · doi:10.1210/jcem.87.6.8556 · Paper page
  16. Lin, 2007, Variable phenotypes associated with aromatase (CYP19) insufficiency in humans, J Clin Endocrinol Metab., 92, 982, 10.1210/jc.2006-1181 · DOI · Paper page
  17. Belgorosky, 2009, Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence, Horm Res., 72, 321
  18. Bulun, 1994, Regulation of aromatase expression in human tissues, Breast Cancer Res Treat., 30, 19, 10.1007/BF00682738 · DOI
  19. Shozu, 1991, A new cause of female pseudohermaphroditism: placental aromatase deficiency, J Clin Endocrinol Metab., 72, 560, 10.1210/jcem-72-3-560 · DOI · Paper page
  20. Bouchoucha, 2014, Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies, Mol Cell Endocrinol., 390, 8, 10.1016/j.mce.2014.03.008 · DOI
  21. Stocco, 2012, Tissue physiology and pathology of aromatase, Steroids., 77, 27, 10.1016/j.steroids.2011.10.013 · DOI · Paper page
  22. Khatri, 2014, Kinetic solvent isotope effect in steady-state turnover by CYP19A1 suggests involvement of compound 1 for both hydroxylation and aromatization steps, FEBS Lett., 588, 3117, 10.1016/j.febslet.2014.06.050 · DOI
  23. Akhtar, 2015, Acyl-carbon bond cleaving cytochrome P450 enzymes: CYP17A1, CYP19A1 and CYP51A1, Adv Exp Med Biol., 851, 107, 10.1007/978-3-319-16009-2_4 · DOI
  24. Klein, 2013, Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem, Front Genet., 4, 12, 10.3389/fgene.2013.00012 · DOI · Paper page
  25. Fernández-Cancio, 2019, A novel homozygous AMRH2 gene mutation in a patient with persistent Müllerian duct syndrome, Sex Dev., 13, 87, 10.1159/000499324 · DOI
  26. Nicolo, 2010, Restoration of mutant cytochrome P450 reductase activity by external flavin, Mol Cell Endocrinol., 321, 245, 10.1016/j.mce.2010.02.024 · DOI
  27. Udhane, 2017, Altered CYP19A1 and CYP3A4 activities due to mutations A115V, T142A, Q153R and P284L in the human P450 oxidoreductase, Front Pharmacol., 8, 580, 10.3389/fphar.2017.00580 · DOI · Paper page
  28. Guengerich, 2009, Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase, Nat Protoc., 4, 1245, 10.1038/nprot.2009.121 · DOI · Paper page
  29. Yim, 2005, A continuous spectrophotometric assay for NADPH-cytochrome P450 reductase activity using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, J Biochem Mol Biol., 38, 366
  30. Marohnic, 2010, Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect, Drug Metab Dispos., 38, 332, 10.1124/dmd.109.030445 · DOI
  31. Faeder, 1973, A rapid micromethod for determination of FMN and FAD in mixtures, Anal Biochem., 53, 332, 10.1016/0003-2697(73)90442-9 · DOI · Paper page
  32. Kagawa, 2011, Efficient expression of human aromatase (CYP19) in E. coli, Methods Mol Biol., 705, 109, 10.1007/978-1-61737-967-3_7 · DOI
  33. Fernandez-Cancio, 2018, Mechanism of the dual activities of human CYP17A1 and binding to anti-prostate cancer drug abiraterone revealed by a novel V366M mutation causing 17,20 lyase deficiency, Pharmaceuticals, 11, 10.3390/ph11020037 · DOI
  34. Lephart, 1991, Assay of aromatase activity, Methods Enzymol., 206, 477, 10.1016/0076-6879(91)06116-K · DOI · Paper page
  35. Velazquez, 2019, Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase, Biochem Biophys Res Commun., 515, 133, 10.1016/j.bbrc.2019.05.127 · DOI
  36. Flück, 2010, Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism, Biochem Biophys Res Commun., 401, 149, 10.1016/j.bbrc.2010.09.035 · DOI · Paper page
  37. Reisch, 2019, Alternative pathway androgen biosynthesis and human fetal female virilization, Proc Natl Acad Sci U S A., 116, 22294, 10.1073/pnas.1906623116 · DOI · Paper page
  38. Miller, 2019, The “backdoor pathway” of androgen synthesis in human male sexual development, Plos Biol., 17, e3000198, 10.1371/journal.pbio.3000198 · DOI
  39. Baronio, 2019, 46,XX DSD due to androgen excess in monogenic disorders of steroidogenesis: genetic, biochemical, and clinical features, Int. J. Mol. Sci, 20, 4605, 10.3390/ijms20184605 · DOI
  40. Parween, 2019, Variability in loss of multiple enzyme activities due to the human genetic variation P284T located in the flexible hinge region of NADPH cytochrome P450 oxidoreductase, Front Pharmacol., 10, 1187, 10.3389/fphar.2019.01187 · DOI
  41. Rochira, 2009, Aromatase deficiency in men: a clinical perspective, Nat Rev Endocrinol., 5, 559, 10.1038/nrendo.2009.176 · DOI · Paper page
  42. Flück, 2019, Human P450 Oxidoreductase Deficiency., 431, 10.1016/B978-0-12-801238-3.64966-8 · DOI

Cited by

See all 28

Metadata

Authors
Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., & Pandey, A. V.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2020-02-15
Volume
105
Issue
4
Pages
e1272-e1290
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3006451876
Cited by
28
References
32
FWCI
1.04
Type
journal article
Language
en
Open access
bronze
Funders
  • Swiss National Science Foundation (31003A-134926)
  • Novartis Foundation for Medical-Biological Research (18A053)
  • Fondo de Investigación Sanitaria (PI05/01647)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype. https://app.cochat.ai/papers/10.1210/clinem/dgaa076
The paper
Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., & Pandey, A. V. (2020). Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa076

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.